Based on the variable basal levels of activated of MEK and IGF1/R pathways, it appears that the synergistic action of AG1024 + U0126 in ALL cells may function in part through additional or off-target activity. The gene discussed is MAP2K7; the disease is acute lymphoblastic leukemia.